The biologic has the potential to deliver effective treatment for adult patients with generalized myasthenia gravis, but it comes at a high cost.
This week, drug maker Alexion announced that the FDA has approved its eculizumab (Soliris) for the treatment of adult patients with generalized myasthenia gravis (gMG), a progressive autoimmune neuromuscular disease, who are anti—acetylcholine receptor (AchR) antibody-positive.
The monoclonal antibody, which also gained approval to treat gMG from the European Medicines Agency in August 2017, is a complement inhibitor. Activation of the complement system plays a major role in the symptoms and potentially life-threatening complications of gMG. Eculizumab selectively inhibits the terminal complement cascade, targeting the cause of the disease.
“Today’s approval is a significant milestone for Alexion and, more importantly, for the subset of patients with anti-AchR antibody-positive gMG who continue to suffer from significant unresolved disease symptoms despite existing treatment options,” said John Orloff, MD, executive vice president and head of research and development at Alexion. “We are proud that we could apply our deep understanding of complement biology to develop Soliris for the treatment of patients with this debilitating neuromuscular disorder.”
Eculizumab is also approved by the FDA to treat paroxysmal nocturnal and atypical hemolytic uremic syndrome, and is the first newly approved drug to treat gMG in more than 60 years. The biologic has the potential to deliver effective treatment for this underserved patient population, but it comes at a high cost; Fierce Pharma has estimated the annual cost of the drug per US patient at $536,629, making the drug among the most expensive therapies in the world (by comparison, Novartis’ newly approved CAR T-cell therapy, tisagenlecleucel, is listed at a price of $475,000).
Seeking to protect its sales of the expensive innovator biologic, Alexion also sought, and obtained, 3 new US patents covering eculizumab. The patents are directed to composition of matter, pharmaceutical formulations, and methods of treatment, and will protect the drug from biosimilar competitors, such as Amgen’s proposed ABP 959, until 2027.
Notably, other biologics—which have cheaper biosimilar competition on the horizon—have the potential to serve as highly effective therapies for gMG. Rituximab has been demonstrated to have long-lasting clinical benefits in patients with drug-resistant gMG. However, rituximab’s developer, Roche, has not sought a gMG indication for the drug.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.